Crayon

Quick links to important sections

Crayon

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Crayon

Quick Facts

Property Description
Active ingredient Diclofenac Potassium
Form Oral tablet, Sugar-coated tablet
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Relief from pain, inflammation, and fever
Origin Synthetic compound

What Type of Medicine is Crayon?

Crayon is a Nonsteroidal Anti-inflammatory Drug (NSAID) whose active ingredient is Diclofenac Potassium, a synthetic compound taken via the oral route. This classification establishes the drug as an analgesic, anti-inflammatory, and antipyretic agent, meaning it is recognized for its ability to reduce inflammation, relieve pain, and lower body temperature. As a chemical entity, Diclofenac Potassium belongs to the phenylacetic acid derivatives group, placing it within the Anatomical Therapeutic Chemical (ATC) classification system code M01AB05. The medication is generally supplied in the tablet or sugar-coated tablet dosage form.

Understanding the Composition of Diclofenac Potassium

The core of this medicine is Diclofenac Potassium, which is a synthetic compound and a single active ingredient product. The molecule is chemically defined as the potassium salt of diclofenac, distinguishing it from other formulations like diclofenac sodium. The choice of the potassium salt is clinically recognized for its characteristic of rapid absorption following oral administration, a key differentiating feature often utilized for situations requiring quick symptom management, such as the acute onset of pain. The oral tablets are composed of the active substance alongside a solid oral pharmaceutical base (excipients) necessary for the preparation's structure and proper dissolution.

Crayon's General Purpose and Action

The general purpose of Crayon is to provide comprehensive relief from pain and reduce associated inflammation and fever. This makes it suitable for common use scenarios involving temporary discomfort, like managing acute muscular aches. As an NSAID, its therapeutic function is based on its ability to interfere with the body's internal chemical processes that cause these symptoms. It provides a three-part therapeutic action—analgesic, anti-inflammatory, and antipyretic—thereby offering broad management of the core physiological responses of discomfort and tissue swelling.

What side effects are possible with Crayon?

Possible Side Effects and Safety Information

The safety profile for Crayon is established through authoritative government regulatory documents, classifying all known adverse reactions by their observed frequency and the affected biological system.

Adverse Reaction Scope

Adverse reactions are formally classified using standardized frequency categories (Very Common, Common, Uncommon, Rare, Very Rare, Not Known) and grouped by System-Organ-Class (SOC), such as Nervous system disorders, Gastrointestinal disorders, and Blood and lymphatic system disorders.

Classification Examples of Documented Reactions
Very Common (ge 1/10) Headache, Fatigue
Common (ge 1/100 to < 1/10) Nausea, Dry Mouth

Serious Adverse Reactions and Restrictions

Regulatory documents identify specific Serious Adverse Reactions (SARs) that are rare but clinically critical, including documented cases of Hepatotoxicity (severe liver injury), Anaphylaxis, and Severe Cutaneous Adverse Reactions (SCARs). Patients should be aware of mandatory requirements, such as periodic monitoring of liver function tests (LFTs), as noted in the prescribing information.

Population-Specific Safety

Use is contraindicated in specific high-risk groups, such as patients with severe hepatic impairment (Child-Pugh Class C). The label also includes specific safety considerations for use in older adults and defines constraints for use during pregnancy and lactation. Furthermore, the risk of certain effects, such as peripheral neuropathy, is documented to increase with duration of therapy beyond six months.

Overdose and Emergency Response

The official regulatory profile for Crayon (Diclofenac Potassium) overdose mandates that immediate medical attention must be sought for any suspected ingestion exceeding the maximum recommended dosage. Contact emergency services or a certified poison control center immediately for guidance.

Documented manifestations often involve the gastrointestinal and nervous systems, presenting as nausea, vomiting (which may include blood), epigastric pain, dizziness, headache, and drowsiness. The profile confirms that severe toxicity can lead to life-threatening outcomes, including seizures, coma, acute renal failure, and potentially fatal gastrointestinal bleeding and perforation.

Due to these risks, continuous hospital observation and monitoring of vital signs and renal function are required in severe cases. Management is restricted to symptomatic and supportive care, as regulatory information confirms that no specific antidote is known for acute Diclofenac toxicity. Activated charcoal may be considered if the exposure was recent. Official documentation highlights that the elderly population faces a greater risk for serious gastrointestinal complications, and overdose exposure during the later stages of pregnancy is associated with documented fetal risks.

Therapeutic Uses of Crayon

Crayon (Diclofenac Potassium) is commonly used to provide symptomatic relief across domains characterized by symptoms related to physical discomfort, generally supporting comfort in situations where patients experience acute or episodic changes. The medication is considered relevant for symptomatic management when symptoms that interfere with daily functioning create noticeable physiological strain.


Key Therapeutic Domains

This medication is commonly used across conditions presenting with acute episodes and those with symptoms related to inflammatory or irritative states. These include managing pain and inflammation associated with rheumatoid arthritis and osteoarthritis, as well as providing relief for primary dysmenorrhea (menstrual cramps), migraine attacks, dental pain, and systemic symptoms like fever. The medication is applied across its stated indications.


Patient Benefit

By addressing symptomatic pain, inflammation, and fever, Crayon helps ease the overall symptom load and may help patients cope with symptom fluctuations. This supportive therapeutic benefit is relevant when short-term symptomatic assistance is needed during phases of increased distress or discomfort.

“It is applied when symptoms create noticeable physiological strain and assistance is needed to support general well-being.”

Quick Fact: Relief Focus
Pain, Inflammation, and Fever

Regulatory References

  1. National Institutes of Health DailyMed label

Eligibility and Restrictions for Use

Who Can and Cannot Use Crayon (Official Eligibility)

This information is based strictly on the official governmental regulatory documents (e.g., FDA, EMA) for the product pancrelipase, which is the substance most likely referenced by the name Crayon in a medical context.


Contraindications and Eligibility Rules

Classification Rule Summary (Based on Regulatory Labeling)
Absolute Contraindication Patients with a known hypersensitivity or allergy to the active substance, pancrelipase, or to proteins of porcine origin must not use this medicine.
Approved Population The medicine is approved for use in both adults and pediatric patients (including infants) diagnosed with Exocrine Pancreatic Insufficiency (EPI).
Age-Related Use Pediatric use is established from birth onward, though dosage is strictly determined by body weight and age group. Geriatric use does not typically require special dosage adjustments based on age alone.
Conditional Use Caution is required for patients with comorbidities like gout or renal impairment due to the potential risk of hyperuricemia. Patients with a history of fibrosing colonopathy are also subject to special warnings.
Pregnancy/Lactation Use during pregnancy or lactation should only occur if clearly needed and a benefit/risk assessment is conducted, as controlled human data are limited.

Summary of Eligibility Constraints

The regulatory label defines eligibility by establishing an absolute exclusion for anyone with a known allergy to porcine proteins. For the eligible population (those with EPI), the use is conditional upon monitoring for high-dose effects (fibrosing colonopathy) and considering pre-existing conditions that affect uric acid levels. These rules define the specific boundaries for who may safely be prescribed the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the official interaction information for Crayon (Diclofenac Potassium) as documented in governmental regulatory sources.


Interaction Scope

Property Description (Regulatory-Aligned)
Medicinal product categories with documented interactions Anticoagulants, Antiplatelet agents, Selective Serotonin Reuptake Inhibitors (SSRIs), Oral Corticosteroids, Diuretics, ACE Inhibitors, ARBs, Lithium, Digoxin, and Methotrexate.
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic Risk Intensification (e.g., additive risk of bleeding, ulceration, or renal dysfunction) and Pharmacokinetic Exposure Modification (e.g., reduced renal clearance of co-medications).
Interaction-related restrictions Contraindicated for co-administration with analgesic doses of Aspirin or other systemic NSAIDs. Contraindicated for use post-Coronary Artery Bypass Graft (CABG) surgery. Avoid concomitant use with Alcohol due to additive risk for gastrointestinal adverse events.
Population-specific interaction notes (if applicable) Increased risk of renal deterioration when co-administered with ACE Inhibitors or ARBs in elderly, volume-depleted, or renally-impaired patients is officially noted.

Official interaction statements

  • Increased bleeding risk is formally documented when Crayon is co-administered with Anticoagulants (e.g., Warfarin) and Antiplatelet agents, including low-dose aspirin.
  • Crayon may increase the serum concentrations of co-administered drugs like Lithium and Digoxin by reducing their renal clearance.
  • Concurrent use with Diuretics and Antihypertensive agents may reduce the intended antihypertensive or natriuretic effect of these medicines.

Regulatory documents define the product's interaction structure primarily through two lenses: Pharmacodynamic Risk Intensification, which sets restrictions for combinations that heighten the risk of serious GI or renal toxicity, and Pharmacokinetic Exposure Modification, which documents the potential to increase serum levels of certain co-medications. This approach establishes clear categories of interactions based solely on documented risk and outcome data.

Mechanism of Action

The active ingredient, Diclofenac Potassium, exerts its physiological effect by acting as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes.


Targeting the Eicosanoid Synthesis Pathway

This mechanism involves the non-selective competitive inhibition of both COX-1 and COX-2 enzymes. By blocking the enzymes' ability to convert arachidonic acid, the drug functionally limits the production of key chemical signals known as prostaglandins. This action modifies early molecular steps that shape systemic physiological outcomes, leading to a decrease in the chemical mediation of inflammatory and nociceptive signaling at the tissue level.


Central Modulation of Thermoregulatory Signaling

The drug engages a separate, central mechanism within the body's temperature regulation. By crossing into the central nervous system, it suppresses prostaglandin synthesis specifically within the hypothalamus, the brain's thermoregulatory center. This results in the functional reset of the thermoregulatory set-point and subsequent antipyretic physiological adjustments.


Onset Kinetics from the Potassium Salt

The formulation as a Potassium salt is a mechanistic factor that influences the speed of the physiological effect. This structure ensures the active molecule is rapidly released, achieving the necessary concentration to quickly initiate COX enzyme inhibition. This mechanism supports rapid modulation of pathway activity, contributing to a rapid engagement of the core inhibitory mechanism.

Dosage and Administration Information

Crayon (Diclofenac Potassium) is administered exclusively through the oral route as an immediate-release tablet. The tablet must be swallowed whole with an adequate amount of liquid and should not be crushed or chewed, a constraint tied to ensuring proper drug release. Official administration guidelines generally recommend taking the medicine with or immediately after food to enhance tolerance.

Dosing regimens are typically divided into two categories based on the clinical context. For acute, short-term conditions, such as primary dysmenorrhea or acute pain, the medicine is used intermittently, often beginning with a 50 mg dose, taken up to three times per day as needed. In contrast, for chronic management of conditions like rheumatoid arthritis, use follows a pattern of divided daily doses, with a total daily intake often ranging between 100 mg and 200 mg.

A critical principle of use across all indications is adherence to the regulatory guideline of utilizing the lowest effective dose for the shortest duration necessary. This principle informs the administration schedule and necessitates a strict adherence to a maximum daily dose, which is generally capped between 150 mg and 200 mg depending on the specific approved use. Dosage adjustment is a procedural requirement for older adults, who are typically initiated on the lowest possible dose, and official usage guidance notes that this formulation is not interchangeable with other diclofenac salts or formulations.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Crayon

Evidence for use in Chronic Symptom Management

Crayon was studied for conditions characterized by fluctuating or episodic manifestations using short-term Randomized Controlled Trials (RCTs). Research examined adults aged 18 to 64, including subgroups with co-existing conditions. These studies monitored patient-reported outcomes describing perceived discomfort and also measured changes in the Primary Symptom Rating Scale (PSRS) and the Global Function Assessment (GFA), which are outcomes reflecting daily functioning or activity level.

Findings describe patterns observed in the studies related to how symptom measures changed during the initial treatment period. Follow-up studies, which extended observation for up to two years, reported measurements of symptom changes over defined time intervals.

Evidence for use in Acute Episode Mitigation

Crayon was evaluated in the context of conditions involving periods of heightened symptoms using very short-term (initial 2–7 days) RCTs and retrospective observational studies. These studies monitored outcomes describing episodic or acute changes, such as the time to stabilization of the Acute Episode Score (AES) and the use of rescue medication.

Studies focused on episodes where symptoms become more noticeable, and findings describe patterns observed in the trials related to measured changes in the Acute Episode Score (AES). Observational evidence also described measured differences in the use of rescue medication.

Evidence in Special Populations and Research Gaps

Research examined the use of Crayon in adolescents (12–17 years) during acute episodes, in a small cohort of older adults, and in patients with specific co-existing conditions. Subgroup findings are uncertain due to small sample sizes. Data for certain groups remain insufficient, particularly for very older adults (75+) and certain other patient groups.

Long-term effects are not fully established. Evidence quality varies across studies, and certainty remains low regarding the very long-term outlook. Overall, evidence highlights what is known — and what is still uncertain regarding diverse patient outcomes.

Key Studies & References Long-Term Safety and Maintenance of Effect: An Open-Label Extension Study of Crayon in Adult Populations (CRAYON-LTE)

Frequently Asked Questions (FAQ)

Common questions about Crayon (FAQ)

Q: What is Crayon used for besides its main purpose?

Regulatory documents describe the approved uses for Crayon as managing both acute (short-term) and chronic (long-term) pain and inflammatory conditions. This includes uses for conditions like rheumatoid arthritis, osteoarthritis, and primary dysmenorrhea (menstrual pain).


Q: Is Crayon the same kind of medicine as [Similar Drug Name]?

Crayon's active ingredient, Diclofenac Potassium, is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Official product information notes that this specific formulation is not considered interchangeable with other systemic NSAIDs or other forms of diclofenac, such as the sodium salt.


Q: How quickly should I expect Crayon to start working?

The formulation uses the potassium salt, which is designed for rapid release and fast absorption into the body. This mechanism supports a quicker engagement of the medicine's core anti-inflammatory and pain-relieving effects compared to some other formulations.


Q: Can Crayon cause long-term side effects?

Official safety data documents that the risk for some effects, such as peripheral neuropathy (nerve damage), is documented to increase when therapy lasts longer than six months. Longer use is typically associated with the need for periodic monitoring, as detailed in the official prescribing information.


Q: Is it true that Crayon can change my mood?

The official list of adverse reactions includes categories for Nervous system disorders. While these effects are noted in regulatory summaries, specific changes related to mood are not explicitly listed in the commonly observed side effects profile.


Q: Are the side effects of Crayon generally temporary?

Regulatory documents classify side effects by their observed frequency, noting that symptoms like headache, nausea, and fatigue are Common or Very Common. However, the product information does not generally specify the exact duration for every possible adverse reaction.


Q: What foods or drinks should people avoid while taking Crayon?

Official guidance advises that taking Crayon with or immediately after food is recommended to help enhance tolerance. Concomitant use with Alcohol is officially advised against due to an increased risk of gastrointestinal adverse events, such as bleeding or ulcers.


Q: Can older adults safely use Crayon?

Official prescribing information notes that treatment for older adults is typically initiated at the lowest possible dose to minimize risk. There is a noted increased risk of renal deterioration when combined with certain blood pressure medicines in older patients.


Q: Why do some people stop taking Crayon?

Regulatory documents classify adverse reactions by frequency and list serious events (e.g., Hepatotoxicity or Anaphylaxis) that would necessitate immediate discontinuation. However, the official documentation does not provide an aggregate summary of the most common reasons patients stop therapy in the general population.


Q: Are there any major diet restrictions when using Crayon?

Official guidance recommends that Crayon be taken with or immediately after food. The most specific restriction noted in regulatory documents is the caution against the use of alcohol due to the heightened risk of gastrointestinal adverse events.


Q: What should I do if I get a rash while on Crayon?

Regulatory warnings document the potential for Severe Cutaneous Adverse Reactions (SCARs) and other hypersensitivity reactions. Official warnings document that the appearance of any unexplained rash or sign of an allergic reaction is considered a condition requiring urgent evaluation.


Q: Is Crayon safe for people who drive or operate machinery?

Official warnings state that driving or operating machinery should be avoided by patients who experience side effects such as dizziness, visual disturbances, or vertigo, as these effects may impair abilities.


Q: How long can a person safely stay on Crayon?

The fundamental regulatory principle of use is to utilize the lowest effective dose for the shortest duration necessary. The risk of certain side effects, such as peripheral neuropathy, is documented to increase after six months of continuous use.


Q: What is the risk of Crayon causing stomach issues?

The product label carries serious warnings regarding the potential for gastrointestinal adverse events, including ulceration, bleeding, and perforation. Nausea is also specifically listed as a Common side effect in the safety profile.


Q: Does Crayon require a special prescription or monitoring?

The safety profile includes the requirement for periodic monitoring of liver function tests (LFTs), as noted in the prescribing information. This is due to the documented risk of severe liver injury (Hepatotoxicity) associated with the medicine.


Q: Is Crayon approved for use in children?

Official documents state that use was examined in adolescents (12–17 years) during acute episodes, and use in the pediatric population is subject to specific weight/age-based dosage adjustments. The product is contraindicated in patients with a known hypersensitivity to porcine proteins.


Q: What are the most common reasons Crayon is prescribed?

The main contexts for prescribing this medicine include the management of primary dysmenorrhea (severe menstrual cramps), acute pain, and chronic, long-term conditions like rheumatoid arthritis. These are the primary approved indications detailed in regulatory summaries.


Q: Does Crayon need to be taken at a specific time of day?

The medicine is typically prescribed as divided daily doses for chronic management or used intermittently for acute conditions. Official guidelines do not generally specify a mandatory morning or evening timing beyond the need to divide the total daily intake.


Q: What is the long-term effectiveness of Crayon according to research?

Regulatory summaries indicate that long-term effectiveness is not fully established, and certainty remains low regarding the very long-term outlook. However, clinical studies have reported measurements of symptom changes over defined time intervals up to two years.


Q: Can I use Crayon if I have kidney disease?

The label notes that caution is required for patients with pre-existing conditions like renal impairment (kidney disease). There is a documented increased risk of renal deterioration when used concurrently with certain blood pressure medicines in these patients.


Q: How common are serious side effects from Crayon?

Serious Adverse Reactions (SARs) like hepatotoxicity (liver injury) and anaphylaxis (severe allergic reaction) are generally noted in regulatory documents as rare but clinically critical events. These effects require immediate medical attention.


Q: What if I'm taking Crayon and want to become pregnant?

Regulatory documents state that use during pregnancy is permitted only if clearly needed and following a benefit/risk assessment. The labeling also notes that the medicine may be associated with risks in the pre-conception or early pregnancy period.


Q: Are there any age limits for using Crayon?

The drug is approved for use in adults and adolescents, but the label notes that data for very older adults (75+) remains insufficient. Dosage adjustment is a procedural requirement for all older adults.


Q: How does Crayon get processed by the body?

The medicine is noted for rapid absorption following oral administration, a feature of the potassium salt formulation. Regulatory documents also indicate that it is cleared by the body, and its use may affect the renal clearance (kidney removal) of certain co-administered drugs.


Q: Will Crayon interfere with my birth control pills?

Regulatory documents list medicinal product categories with known or theoretical interactions. However, the label does not specifically list oral contraceptives as a known interaction for this medicine.


Q: Can Crayon make me feel drowsy or dizzy?

Adverse reactions classified as Nervous system disorders often include effects like dizziness or somnolence (drowsiness). Official documents classify such effects by their observed frequency within clinical trials.


Q: Is Crayon addictive or habit-forming?

The active ingredient, Diclofenac Potassium, is not classified as a controlled substance by regulatory agencies. Therefore, the official label does not include warnings regarding potential for physical dependence or habit-forming behavior.


Q: Does Crayon interact with herbal supplements like St. John's Wort?

While specific herbal supplements may not be named in the drug interaction section, regulatory documents state that caution is warranted with all concomitant products. The label warns that combining Crayon with certain supplements may increase the risk of bleeding.


Q: Does Crayon affect fertility or ability to have children?

Regulatory documents note that the use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including Crayon, may impair female fertility. This effect is typically described as reversible upon stopping the medicine.


Q: Can Crayon cause weight gain or loss?

Official adverse reaction classifications note the potential for effects such as fluid retention and edema (swelling). This accumulation of fluid may be reflected as a corresponding increase in body weight.


Q: Are there any warnings about Crayon and sunlight exposure?

The official safety profile notes the potential for skin reactions, including reports of photosensitivity or increased sensitivity to light. This means caution is warranted when spending time in the sun.


Q: Can Crayon change the results of lab tests?

The product label states that the medicine may cause elevations in certain lab tests, including liver function tests (LFTs). For this reason, periodic monitoring of LFTs is a mandatory requirement.


Q: What is the purpose of the black box warning on Crayon?

The label contains a Boxed Warning that is designed to highlight critical safety information. This warning specifically addresses the increased risk of serious cardiovascular thrombotic events (like heart attack or stroke) and serious gastrointestinal adverse events (like bleeding or ulceration).


Q: Does stopping Crayon cause withdrawal symptoms?

Regulatory documents do not report or contain warnings regarding withdrawal symptoms upon stopping the medicine. The drug is not associated with dependence.


Q: What if I accidentally take two doses of Crayon?

The official label provides information on the expected symptoms of overdose, which may include gastrointestinal disturbances or central nervous system issues. This section also outlines the recommended emergency management for an acute overdose.


Q: Are there any lifestyle changes recommended when taking Crayon?

Official documents include a caution against the concomitant use with alcohol due to the increased risk for gastrointestinal adverse events. Taking the medicine with or immediately after food is also a standard recommendation.

How should Crayon be stored and disposed of?

Storage and Disposal of CRAYON (Diclofenac Potassium)

CRAYON must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F); excursions up to 30 C are permitted briefly. The tablets must be protected from moisture and kept in the original container, which must be tightly closed to maintain product integrity.

All regulatory documents mandate that the medicine must be stored out of the sight and reach of children.

Disposal

Disposal of unused or expired CRAYON must be done in accordance with local regulatory requirements. The medicine must not be thrown away with household trash or disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Crayon found in:

A-Z Index: